Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00257751
Status:
COMPLETED
Last Update Posted:
2011-07-06
First Post:
2005-11-22
Brief Title:
Different Regimen of AprotinineTrasylol Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel Plavix
Sponsor:
Oslo University Hospital
Organization:
Oslo University Hospital
Study Overview
Official Title:
Different Regimen of AprotinineTrasylol Administration in Patients Receiving
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clopidogrel Plavix a platelet ADP receptor antagonist has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEMI An increasing number of patients are referred to emergent or urgent CABG and several studies as well as our own experience have shown that preoperative administration of irreversible platelets inhibitors increase the risk of bleeding complications following CABG
Detailed Description:
Aprotinine Trasylol is a potent antifibrinolytic agent known to reduce bleeding after cardiac surgery The most commeon practice is to give Trasylol in high doses immediately before surgery during the operation and during the first postoperative hours However it has also been shown that there is a hemostatic effect of the drug when given in a lower dose postoperatively but this remains unclear
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| APROT04 | None | None | None |